Table 3.
List of immunocytokines investigated for multiple myeloma.
| Drug name | Target | Effector moiety | Development state | Clinical trial | Treatment regimen | Status | References |
|---|---|---|---|---|---|---|---|
| TAK-573 | CD38 | Attenuated IFNα2b (Attenukine™) | Clinical | NCT03215030; phase 1/2 | TAK-573 mono and TAK-573 + dex | Recruiting | (162, 164) |
| IL2-αCD38-αCD38-scTRAIL | CD38 | TRAIL & IL-2 | Preclinical | - | - | - | (165) |
| Anti-CD138-IFNα14 Anti-CD138-IFNα2 Anti-CD138-IFNα2YNS |
CD138 | IFNα14 IFNα2 IFNα2YNS |
Preclinical | - | - | - | (161, 163) |
| 20-C2-2b | CD20 & HLA-DR | IFNα2b | Preclinical | - | - | - | (160) |
| C2-2b-2b | HLA-DR | Tetrameric IFNα2b | Preclinical | - | - | - | (147) |
| L19-TNFα L19-IL2 |
Fibronectin extra-domain B | TFNα IL-2 |
Preclinical | - | - | - | (166) |
dex, dexamethasone; mono, monotherapy.